Literature DB >> 3257985

Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin.

A Pezzutto1, P S Rabinovitch, B Dörken, G Moldenhauer, E A Clark.   

Abstract

As B cells mature during ontogeny the CD22 human differentiation Ag is exported from the cytoplasm onto the membrane. Surface expression is lost in terminal differentiation and after activation. In tonsils, CD22 is expressed on the surface of 60 to 80% of the dense B cells. Some IgM+ dense cells, however, and buoyant in vivo activated B cells are CD22-. This differential expression of CD22 and the finding that an anti-CD22 mAb augmented anti-Ig induced B cell proliferation suggested that CD22 may play a role in B cell activation. In this study we have found that CD22+ but not CD22- B cells could be triggered by anti-IgM or anti-IgD to have increased free intracellular calcium ([Ca2+]i). The presence of CD22 rather than of IgD seems to determine the ability of B cells to respond to anti-Ig with a [Ca2+]i flux. Also the proliferative response to anti-Ig or anti-Ig + B cell growth factor was restricted to the CD22+ population. Anti-CD22 mAb, although not inducing [Ca2+]i on their own after binding to B cells, did augment [Ca2+]i fluxes by anti-Ig when cross-linked. Together these results suggest that CD22 may regulate triggering of B cells through surface Ig perhaps by acting as a "bridge" to transmit an early signal into the cytoplasm.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257985

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Surface molecules involved in B lymphocyte function.

Authors:  P Möller; A Eichelmann; G Moldenhauer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.

Authors:  Xing Du; Richard Beers; David J Fitzgerald; Ira Pastan
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

3.  Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.

Authors:  R Stein; E Belisle; H J Hansen; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

4.  Functional evaluation of CD19- and CD22-negative variants of B-lymphoid cell lines.

Authors:  S Kiesel; A Pezzutto; R Haas; G Moldenhauer; B Dörken
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

5.  Btk dosage determines sensitivity to B cell antigen receptor cross-linking.

Authors:  A B Satterthwaite; H Cheroutre; W N Khan; P Sideras; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

6.  Calcium mobilization in activated mast cells monitored by flow cytometric analysis.

Authors:  G L Rossi; D J Young; S I Wasserman; K E Barrett
Journal:  Agents Actions       Date:  1990-11

Review 7.  The B cell antigen receptor complex: mechanisms and implications of tyrosine kinase activation.

Authors:  J Tseng; Y J Lee; B J Eisfelder; M R Clark
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

8.  B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse.

Authors:  Noriko Asano; Manabu Fujimoto; Norihito Yazawa; Senji Shirasawa; Minoru Hasegawa; Hitoshi Okochi; Kunihiko Tamaki; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

9.  CD22 associates with the human surface IgM-B-cell antigen receptor complex.

Authors:  C Leprince; K E Draves; R L Geahlen; J A Ledbetter; E A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

Review 10.  CD22: an inhibitory enigma.

Authors:  Jennifer A Walker; Kenneth G C Smith
Journal:  Immunology       Date:  2007-12-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.